Bayesian Capital Management’s AtriCure ATRC Stock Holding History

Bayesian Capital Management’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-11,300	Closed	-$344K	–	727
2024 Q1	$344K	Buy	+11,300	New	+$379K	0.03%	521
2023 Q4	–	Sell	-7,900	Closed	-$346K	–	746
2023 Q3	$346K	Buy	+7,900	New	+$385K	0.04%	437
2017 Q1	–	Sell	-10,400	Closed	-$204K	–	405
2016 Q4	$204K	Buy	+10,400	New	+$188K	0.05%	515

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bayesian Capital Management's ATRC Position: Q2 2024 in Review

Bayesian Capital Management sold out of AtriCure (ATRC) in Q2 2024, closing a stake of 11,300 shares — an estimated $344K sold.

Bayesian Capital Management first reported a position in ATRC in Q4 2016 and held it in 3 quarters. The position peaked at $346K in Q3 2023. 197 funds tracked by Wall St. Rank hold ATRC as of Q2 2024.

Bayesian Capital Management reported no remaining AtriCure position as of Q2 2024 after selling out during the quarter.
Bayesian Capital Management sold 11,300 AtriCure shares in Q2 2024, an estimated $344K.
Bayesian Capital Management first reported a position in AtriCure in Q4 2016 and held it in 3 quarters.
Bayesian Capital Management's AtriCure position peaked at $346K in Q3 2023.
197 funds tracked by Wall St. Rank held AtriCure as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.